Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rovalpituzumab, an antibody targeting DLL3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Glembatumumab, an antibody targeting GPNMB.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvratoxumab, an antibody targeting Staphylococcus aureus Toxin A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Depatuxizumab, an antibody targeting EGFR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Otilimab, an antibody targeting CSF2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ontamalimab, an antibody targeting MADCAM1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Birtamimab, an antibody targeting SAA1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Upinitatug, an antibody targeting SLC34A2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sabatolimab, an antibody targeting TIM-3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tusamitamab, an antibody targeting CEACAM5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Briakinumab, an antibody targeting IL-12/23p40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Maftivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.